- Results demonstrate meaningful and durable efficacy signal in a highly challenging indication - A higher dose level of pelareorep led to 50% 24-month median overall survival (mOS) and
/PRNewswire/ Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADRĀ® artificial intelligence ("A.I.") platform.